Differential resistance of melanoma cells to treatment with recombinant IFN-alpha2b and leukocyte IFN.
2007 (English)In: Anticancer Res, ISSN 0250-7005, Vol. 27, no 4B, 2109-14 p.Article in journal (Refereed) Published
BACKGROUND: Interferon-alpha (IFN-alpha) subtypes bind to the same receptor and are expected to have the same biological functions. Whether or not leukocyte IFN, containing six major IFN-alpha proteins had the same anti-tumor effect as one subtype, recombinant IFN-alpha2b, was investigated. MATERIALS AND METHODS: Three melanoma lines were treated with both types of IFN, and the effect on proliferation and survival was estimated both after short-term and prolonged treatment. RESULTS: All the melanoma cell lines were sensitive to the antiproliferative effects of both IFN species during short-term treatment. However, upon prolonged culture, the frequency of resistant colony formation was significantly higher in cultures treated with IFN-alpha2b compared to those treated with leukocyte IFN. There was a qualitative difference between the resistant colonies selected by the two IFN species with respect to morphology, growth rate and sensitivity to apoptosis. CONCLUSION: The development of resistant clones occurred at a lower rate during long-term treatment with leukocyte IFN containing six major subtypes of IFN-alpha as compared to IFN-alpha2b.
Place, publisher, year, edition, pages
2007. Vol. 27, no 4B, 2109-14 p.
Antineoplastic Agents/*pharmacology, Cell Growth Processes/drug effects, Drug Resistance; Neoplasm, Humans, Interferon Alfa-2b/*pharmacology, Interferon-alpha/*pharmacology, Melanoma/*drug therapy/pathology, Tumor Cells; Cultured
IdentifiersURN: urn:nbn:se:umu:diva-16482PubMedID: 17695493OAI: oai:DiVA.org:umu-16482DiVA: diva2:156155